ArticleJournal of minimal access surgery2026
Minimally invasive adrenalectomy for the treatment of large pheochromocytoma: A single-centre experience.
Article in Journal of minimal access surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPheochromocytoma (PHEO) arises from the chromophil cells of the adrenal medulla. Surgical resection is the primary treatment for PHEO. Our work aimed to investigate the efficacy and safety of minimally invasive surgery in patients with large PHEO. PATIENTS AND
methodsThis study included patients who were referred to our centre, General Surgery Outpatient Clinic, between January 2007 and December 2023, who were interviewed by a multidisciplinary endocrine board, who were diagnosed with PHEO by clinical and laboratory examination and who decided to undergo unilateral laparoscopic adrenalectomy.
resultsA total of 275 patients had laparoscopic unilateral adrenalectomy during the research period. A total of 75 patients were operated on for PHEO. The PHEO group with a tumour size <6 cm consists of 46 patients, while the PHEO group with a tumour size >6 cm consists of 29 patients. The groups showed similar complications, conversion rates and hospital stays. We used multiple regression analysis to identify the independent predictors of prolonged operation time. The tumour size 6-8 cm (odds ratio [OR], 3.214; 95% confidence interval [CI], 1.240-10.819; P < 0.021) and the tumour size ≥8 cm (OR, 6.343; 95% CI, 1.175-34.237; P < 0.031) were the significant predictors of prolonged operation time.
conclusionMinimally invasive surgery can be considered the treatment of choice for <6 cm and ≥6 cm PHEO. Tumour size ≥8 cm and tumour size ≥6-8 cm for PHEO are predictive risk factors for prolonged operative time in LA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.